{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:15:56Z","timestamp":1783160156501,"version":"3.54.6"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302370"],"award-info":[{"award-number":["82302370"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572399"],"award-info":[{"award-number":["82572399"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82427808"],"award-info":[{"award-number":["82427808"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013290","name":"National Key Research and Development Program of China Stem Cell and Translational Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013290","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20230836"],"award-info":[{"award-number":["BK20230836"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1205803"],"award-info":[{"award-number":["2022YFA1205803"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2406504"],"award-info":[{"award-number":["2022YFC2406504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1205802"],"award-info":[{"award-number":["2022YFA1205802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jconrel.2026.114982","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T05:26:31Z","timestamp":1777785991000},"page":"114982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CXCR4-targeted lipid nanozymes for metastasis blockade and immune microenvironment reprogramming in hematological malignancies"],"prefix":"10.1016","volume":"395","author":[{"given":"Mengjun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingze","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2026.114982_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.217131","article-title":"Advances in optical imaging and nanotherapeutic technologies for hematological malignancies: from diagnosis to precision treatment","volume":"547","author":"Kang","year":"2026","journal-title":"Coord. Chem. Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0015","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202515700","article-title":"Targeting the dynamics between TAMs and CAR-T cells in solid tumor therapies","volume":"13","author":"Zhang","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2026.114982_bb0020","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fimmu.2019.00156","article-title":"Molecular players in hematologic tumor cell trafficking","volume":"10","author":"Redondo-Mu\u00f1oz","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2026.114982_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101106","article-title":"Fe3O4@Pt nanozymes combining with CXCR4 antagonists to synergistically treat acute myeloid leukemia","volume":"37","author":"Kong","year":"2021","journal-title":"Nano Today"},{"issue":"2","key":"10.1016\/j.jconrel.2026.114982_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m\u2019s Macroglobulinema: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0035","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/leu.2008.299","article-title":"CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers","volume":"23","author":"Burger","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jconrel.2026.114982_bb0040","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2425795122","article-title":"Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists","volume":"122","author":"Sang","year":"2025","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"22","key":"10.1016\/j.jconrel.2026.114982_bb0045","doi-asserted-by":"crossref","first-page":"15189","DOI":"10.1021\/acs.jmedchem.3c01128","article-title":"Development of N-terminally modified variants of the CXCR4-antagonistic peptide EPI-X4 for enhanced plasma stability","volume":"66","author":"Harms","year":"2023","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0050","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in hematologic malignancies: achievements, challenges and future prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.jconrel.2026.114982_bb0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2020-142978","article-title":"Trends in inpatient chemotherapy hospitalizations, cost and mortality for patients with hematological malignancies: insights from the national inpatient sample","volume":"136","author":"Mohyuddin","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jconrel.2026.114982_bb0060","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.1016\/S2352-3026(24)00247-3","article-title":"Radiotherapy for haematological malignancies","volume":"11","author":"Dee","year":"2024","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114982_bb0065","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.20.03106","article-title":"Immunotherapy for hematologic malignancies","volume":"39","author":"Craddock","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114982_bb0070","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(18)30051-6","article-title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-021-01148-5","article-title":"Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia","volume":"14","author":"Aitken","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.114982_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109979","article-title":"Hallmarks of cancer resistance","volume":"27","author":"Tufail","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.jconrel.2026.114982_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.844866","article-title":"Mechanisms of MHC-I downregulation and role in immunotherapy response","volume":"13","author":"Taylor","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.114982_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2026.114982_bb0095","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1021\/acs.chemrev.4c00882","article-title":"Rational Design of Nanozymes for engineered Cascade catalytic Cancer therapy","volume":"125","author":"Jia","year":"2025","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2026.114982_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.216674","article-title":"Recent progress of advanced nanozymes for targeted oncotherapy and synergistic immunotherapy","volume":"536","author":"Zhang","year":"2025","journal-title":"Coord. Chem. Rev."},{"issue":"10","key":"10.1016\/j.jconrel.2026.114982_bb0105","doi-asserted-by":"crossref","DOI":"10.26599\/NR.2025.94908016","article-title":"E5 peptide-functionalized platinum nanozymes mediate immune microenvironment reprogramming in B-cell lymphoma","volume":"18","author":"Wang","year":"2025","journal-title":"Nano Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0110","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41467-023-37150-3","article-title":"Mechano-boosting nanomedicine antitumour efficacy by blocking the reticuloendothelial system with stiff nanogels","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0115","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-025-02368-w","article-title":"Nanomedicine in Cancer therapeutics: current perspectives from bench to bedside","volume":"24","author":"Abdullah","year":"2025","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.jconrel.2026.114982_bb0120","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/s44222-024-00205-1","article-title":"Designing nanozymes for in vivo applications","volume":"2","author":"Zhang","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40364-023-00475-8","article-title":"Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies","volume":"11","author":"Wang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.jconrel.2026.114982_bb0130","doi-asserted-by":"crossref","first-page":"1674818","DOI":"10.3389\/fimmu.2025.1674818","article-title":"The role of immune checkpoint molecules in cancers","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114982_bb0135","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res."},{"issue":"21","key":"10.1016\/j.jconrel.2026.114982_bb0140","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood.V120.21.565.565","article-title":"Myeloid derived suppressor cells (MDSCs) regulate tumor growth, immune response and regulatory T cell (Treg) development in the multiple myeloma bone marrow microenvironment","volume":"120","author":"Gorgun","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jconrel.2026.114982_bb0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"19","key":"10.1016\/j.jconrel.2026.114982_bb0150","doi-asserted-by":"crossref","first-page":"9669","DOI":"10.3390\/ijms26199669","article-title":"Limitations of CAR-T-cell therapy in hematologic malignancies: focusing on antigen escape and T-cell dysfunction","volume":"26","author":"Lin","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.jconrel.2026.114982_bb0155","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41419-024-06939-5","article-title":"Oxidative cell death in cancer: mechanisms and therapeutic opportunities","volume":"15","author":"An","year":"2024","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114982_bb0160","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"43","key":"10.1016\/j.jconrel.2026.114982_bb0165","doi-asserted-by":"crossref","first-page":"19070","DOI":"10.1002\/anie.202008604","article-title":"PlatinER: a highly potent anticancer platinum(II) complex that induces endoplasmic reticulum stress driven immunogenic cell death","volume":"59","author":"Tham","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"issue":"11","key":"10.1016\/j.jconrel.2026.114982_bb0170","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/cac2.70064","article-title":"Mechanism and role of regulated cell death in tumor immunity and immunotherapy","volume":"45","author":"Hu","year":"2025","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0175","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40364-025-00778-y","article-title":"Targeting the chemokine receptor CXCR4 for cancer therapies","volume":"13","author":"Rueda","year":"2025","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0180","doi-asserted-by":"crossref","first-page":"17033","DOI":"10.1038\/sigtrans.2017.33","article-title":"Targeting the CXCR4\/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression","volume":"2","author":"Guo","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"45","key":"10.1016\/j.jconrel.2026.114982_bb0185","doi-asserted-by":"crossref","first-page":"1905480","DOI":"10.1002\/adfm.201905480","article-title":"CXCR4-enriched Nano-trap targeting CXCL12 in lung for early prevention and enhanced photodynamic therapy of breast cancer metastasis","volume":"29","author":"Wang","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2026.114982_bb0190","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood-2019-130029","article-title":"Deregulated CXCR4-CXCL12 signaling impacts on the pathogenesis of DLBCL","volume":"134","author":"Pansy","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jconrel.2026.114982_bb0195","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1476-4598-5-56","article-title":"Stromal derived Factor-1 (SDF-1\/CXCL12) and CXCR4 in renal cell carcinoma metastasis","volume":"5","author":"Pan","year":"2006","journal-title":"Mol. Cancer"},{"issue":"41","key":"10.1016\/j.jconrel.2026.114982_bb0200","doi-asserted-by":"crossref","first-page":"27917","DOI":"10.1021\/acsnano.4c05079","article-title":"A dual-function LipoAraN-E5 coloaded with N4-myristyloxycarbonyl-1-\u03b2-d-arabinofuranosylcytosine (AraN) and a CXCR4 antagonistic peptide (E5) for blocking the dissemination of acute myeloid leukemia","volume":"18","author":"Wang","year":"2024","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.jconrel.2026.114982_bb0205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1365-2141.2012.09050.x","article-title":"A novel function for the haemopoietic supportive murine bone marrow MS-5 mesenchymal stromal cell line in promoting human vasculogenesis and angiogenesis","volume":"157","author":"Zhou","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.jconrel.2026.114982_bb0210","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2013-03-493924","article-title":"The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization","volume":"123","author":"Hoellenriegel","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114982_bb0215","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ni.2017","article-title":"CXCL12 secretion by bone marrow stromal cells is dependent on cell contact and mediated by connexin-43 and connexin-45 gap junctions","volume":"12","author":"Schajnovitz","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2026.114982_bb0220","first-page":"526","article-title":"A biomimetic nanocomposite with enzyme-like activities and CXCR4 antagonism efficiently enhances the therapeutic efficacy of acute myeloid leukemia","volume":"18","author":"Kong","year":"2022","journal-title":"Bioact. Mater."},{"issue":"16","key":"10.1016\/j.jconrel.2026.114982_bb0225","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/bloodadvances.2023010476","article-title":"Tetraspanins set the stage for bone marrow microenvironment\u2013induced chemoprotection in hematologic malignancies","volume":"7","author":"Quagliano","year":"2023","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.jconrel.2026.114982_bb0230","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood-2002-03-0844","article-title":"Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a","volume":"100","author":"Graf","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2026.114982_bb0235","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eng.2021.06.020","article-title":"Engineered vasculature for organ-on-a-chip systems","volume":"9","author":"Aazmi","year":"2022","journal-title":"Engineering"},{"issue":"5","key":"10.1016\/j.jconrel.2026.114982_bb0240","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/sj.leu.2401729","article-title":"Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers","volume":"14","author":"Bradstock","year":"2000","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jconrel.2026.114982_bb0245","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1039\/D0CS00718H","article-title":"Engineering nanomedicine for glutathione depletion-augmented cancer therapy","volume":"50","author":"Xiong","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"30","key":"10.1016\/j.jconrel.2026.114982_bb0250","doi-asserted-by":"crossref","first-page":"2419673","DOI":"10.1002\/adma.202419673","article-title":"Engineered nanozymes with asymmetric MnOCe sites for intratumorally leveraged multimode therapy","volume":"37","author":"Ye","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114982_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202520580","article-title":"Liquid metal nanoparticles-mediated mitochondrial damage enhances immunogenic cell death for cancer vaccine therapy","author":"Qi","year":"2026","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2026.114982_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122369","article-title":"Biomimetic Prussian blue nanocomplexes for chemo-photothermal treatment of triple-negative breast cancer by enhancing ICD","volume":"303","author":"Long","year":"2023","journal-title":"Biomaterials"},{"issue":"9","key":"10.1016\/j.jconrel.2026.114982_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004389","article-title":"Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models","volume":"10","author":"Chen","year":"2022","journal-title":"J. Immunother. Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003858?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926003858?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T09:21:28Z","timestamp":1783156888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926003858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":53,"alternative-id":["S0168365926003858"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114982","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR4-targeted lipid nanozymes for metastasis blockade and immune microenvironment reprogramming in hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.114982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114982"}}